Experiences of treatment of age related macular degeneration with concomitant myopia
Purpose: to assess the changes in visual functions in patients with age related macular degeneration (AMD) and medium to high degree myopia treated with a peptide bioregulator and a multivitamin complex. Material and methods. 60 patients (120 eyes) aged 44 to 79 with age-related changes in the retin...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Real Time Ltd
2019-03-01
|
| Series: | Российский офтальмологический журнал |
| Subjects: | |
| Online Access: | https://roj.igb.ru/jour/article/view/227 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850047618604859392 |
|---|---|
| author | I. B. Alekseev Ju. A. Nam |
| author_facet | I. B. Alekseev Ju. A. Nam |
| author_sort | I. B. Alekseev |
| collection | DOAJ |
| description | Purpose: to assess the changes in visual functions in patients with age related macular degeneration (AMD) and medium to high degree myopia treated with a peptide bioregulator and a multivitamin complex. Material and methods. 60 patients (120 eyes) aged 44 to 79 with age-related changes in the retina treated with peptide bioregulator and/or multivitamin complex were tested for changes of visual functions. The patients, examined before and after treatment with both, were divided into 2 groups depending on treatment type (peptide plus multivitamin vs. multivitamin alone), which were further subdivided into two subgroups depending on the axial length of the eyeball (less than 26.5 mm vs. 26.5 mm or more). Results. A positive response to the therapy (increased visual acuity and improved perimetic parameters) was revealed in patients of both groups with AL < 26.5 mm), which may be accounted for by an initially better state of the retina. The patients of the subgroup with AL 26.5 mm) showed a significant improvement of uncorrected visual acuity, but best corrected visual acuity remained practically the same. Conclusions. The proposed treatment with a polypeptide bioregulator in combination with a multivitamin complex can be used in AMD and myopic patients with retinal pathology. |
| format | Article |
| id | doaj-art-136a5ee7d03c4550b668213e56e9dec0 |
| institution | DOAJ |
| issn | 2072-0076 2587-5760 |
| language | Russian |
| publishDate | 2019-03-01 |
| publisher | Real Time Ltd |
| record_format | Article |
| series | Российский офтальмологический журнал |
| spelling | doaj-art-136a5ee7d03c4550b668213e56e9dec02025-08-20T02:54:10ZrusReal Time LtdРоссийский офтальмологический журнал2072-00762587-57602019-03-01121818510.21516/2072-0076-2019-12-1-81-85209Experiences of treatment of age related macular degeneration with concomitant myopiaI. B. Alekseev0Ju. A. Nam1Russian Medical Academy of Continuing Professional EducationRussian Medical Academy of Continuing Professional EducationPurpose: to assess the changes in visual functions in patients with age related macular degeneration (AMD) and medium to high degree myopia treated with a peptide bioregulator and a multivitamin complex. Material and methods. 60 patients (120 eyes) aged 44 to 79 with age-related changes in the retina treated with peptide bioregulator and/or multivitamin complex were tested for changes of visual functions. The patients, examined before and after treatment with both, were divided into 2 groups depending on treatment type (peptide plus multivitamin vs. multivitamin alone), which were further subdivided into two subgroups depending on the axial length of the eyeball (less than 26.5 mm vs. 26.5 mm or more). Results. A positive response to the therapy (increased visual acuity and improved perimetic parameters) was revealed in patients of both groups with AL < 26.5 mm), which may be accounted for by an initially better state of the retina. The patients of the subgroup with AL 26.5 mm) showed a significant improvement of uncorrected visual acuity, but best corrected visual acuity remained practically the same. Conclusions. The proposed treatment with a polypeptide bioregulator in combination with a multivitamin complex can be used in AMD and myopic patients with retinal pathology.https://roj.igb.ru/jour/article/view/227age-related macular degenerationmyopiapeptide bioregulatorsmultivitamin complex |
| spellingShingle | I. B. Alekseev Ju. A. Nam Experiences of treatment of age related macular degeneration with concomitant myopia Российский офтальмологический журнал age-related macular degeneration myopia peptide bioregulators multivitamin complex |
| title | Experiences of treatment of age related macular degeneration with concomitant myopia |
| title_full | Experiences of treatment of age related macular degeneration with concomitant myopia |
| title_fullStr | Experiences of treatment of age related macular degeneration with concomitant myopia |
| title_full_unstemmed | Experiences of treatment of age related macular degeneration with concomitant myopia |
| title_short | Experiences of treatment of age related macular degeneration with concomitant myopia |
| title_sort | experiences of treatment of age related macular degeneration with concomitant myopia |
| topic | age-related macular degeneration myopia peptide bioregulators multivitamin complex |
| url | https://roj.igb.ru/jour/article/view/227 |
| work_keys_str_mv | AT ibalekseev experiencesoftreatmentofagerelatedmaculardegenerationwithconcomitantmyopia AT juanam experiencesoftreatmentofagerelatedmaculardegenerationwithconcomitantmyopia |